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Neonatal intensive care has advanced rapidly in the last 40years, with dramatic decreases
in mortality and morbidity; however, for neonatal seizures, neither therapies nor outcomes
have changed signiﬁcantly. Basic and clinical studies indicate that seizures in neonates
have long-term neurodevelopmental and psychiatric consequences, highlighting the need
for novel pharmacotherapeutics. First-line treatments targeting GABAA receptors, like bar-
biturates and benzodiazepines, are limited in their efﬁcacy and carry signiﬁcant risks to the
developing brain. Here, we review the use of current GABA agonist therapies for neona-
tal seizures and suggest other treatment strategies given recent developments in the
understanding of disease pathogenesis. One promising avenue is the indirect manipula-
tion of the GABAergic system, via the modulation of neuronal Cl  gradients, by targeting
the cation-Cl  cotransporters (NKCC1 and KCC2) or their regulatory signaling molecules.
This strategy might yield a novel class of more efﬁcacious anti-epileptics with fewer side
effects by speciﬁcally addressing disease pathophysiology. Moreover, this strategy may
have ramiﬁcations for other adult seizure syndromes in which GABA receptor-mediated
depolarizations play a pathogenic role, such as temporal lobe epilepsy.
Keywords: seizure, GABA, neonatal seizure, bumetanide, NKCC1, KCC2,WNK kinase, SPAK/OSR1 kinase
CURRENT GABA AGONISTS AND PRODRUGS
(BENZODIAZEPINES AND BARBITURATES) ARE
INADEQUATE IN THE TREATMENT OF NEONATAL SEIZURES
Seizures are the most common neurological emergency in the
neonate, with an estimated prevalence of 1.8–5 seizures/1000 live
birthsintheUS(Jensen,2009).Infact,thelifespanriskof seizures
is highest in the neonatal period. There are many conditions
that may cause neonatal seizures, the most common of which
is hypoxia/ischemia (Ronen et al., 1999; Tekgul et al., 2006) caus-
ing white matter injury (Figure 1). Seizures in the newborn can
cause permanent and severe cognitive and behavioral abnormali-
ties,aswellasenhancedepileptogenicitylaterinlife(Baram,2003;
Holmes,2004;Swann,2005),underliningtheimportanceof effec-
tive therapy. Although neonatal seizures have a different etiology
thanadultseizures,currentstandardtherapyinvolvescompounds
whose efﬁcacy has only been well established in older patients.
Benzodiazepines and barbiturates are the most common ﬁrst-line
therapiesforneonatalseizures;however,theefﬁcacyofthesedrugs
intreatingseizuresinthenewbornisnotsupportedbyrobustevi-
dence. The use of these drugs may have signiﬁcant short- and
long-term effects on brain development.
Currenttherapyforneonatalseizuresisusuallyfocusedonearly
treatment with benzodiazepines and barbiturates. These drugs
generally exert their effects via modulation of GABA action at the
GABAA receptor,orbyantagonismof NMDAreceptors.Although
these drugs are effective in adults, they do not control neonatal
seizureswell.Whengivenasmonotherapy,phenobarbitalcontrols
seizures in less than half of newborns (Painter et al., 1999). In a
study examining six neonates treated with second-line benzodi-
azepines,none responded to this medication (Boylan et al.,2004).
A Cochrane review concluded that there was little evidence from
the literature that supported the use of these drugs in treating
neonatal seizures (Booth and Evans, 2004). Furthermore, some
have suggested that benzodiazepines and barbiturates may resolve
the outward clinical symptoms of seizures due to sedation with-
out correcting underlying abnormal brain activity, exacerbating
“electroclinical dissociation”between clinical symptoms and elec-
trographic recording and leading to an overestimation of the true
efﬁcacy of these drugs (Boylan et al.,2002).
Developmentalchangesintheexpressionandactivityofneuro-
transmittersandtheirreceptorsprovidesomeinsightintothebasis
of theincreasedsusceptibilityof theneonatalbraintoseizuresand
the relative inefﬁcacy of benzodiazepines and barbiturates in con-
trolling them. Developmentally regulated ion channel conﬁgura-
tions that facilitate easier depolarization and an increased reliance
on glutamatergic transmission together increase the excitability
of the neonatal brain, putatively to promote synaptogenesis, but
simultaneously conferring a disposition to seizures (Rakhade and
Jensen, 2009). Differences in GABA signaling in the immature
brain also contribute to its overall enhanced excitability. GABA
is the major inhibitory neurotransmitter in the adult central ner-
vous system, but its receptors and synthetic enzyme do not reach
maximallevelsofexpressionuntilthefourthpostnatalweekinrats
(Swannetal.,1989;Brooks-Kayaletal.,2001).Furthermore,while
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FIGURE 1 | Magnetic resonance imaging (MRI) of neonatal
hypoxic-ischemia. Neonatal hypoxic-ischemia is a common cause of white
matter injury, the underlying factor in the development of neonatal seizures.
These manifest on MRI as either punctate white matter lesions (red circles;
seen onT1-weighted MRI imaging) or diffuse excessive high signal intensity
(white square; seen onT2-weighted MRI imaging). Reprinted from
Wisnowski et al. (2013) under the terms of the Creative Commons
Attribution License.
GABA hyperpolarizes adult neurons, it can depolarize neonatal
neuronsinvivo(Loturcoetal.,1995).Thismayexplainwhybenzo-
diazepines and barbiturates, which are GABAA receptor agonists,
have limited efﬁcacy in controlling neonatal seizures.
SHORT-TERM SIDE EFFECTS OF BENZODIAZEPINES AND
BARBITURATES
Inadditiontolimitedefﬁcacy,agrowingbodyofevidencesuggests
thatbenzodiazepinesandbarbituratescauseshort-andlong-term
harm to the developing neonatal brain. Cellular and neuromor-
phological effects of antiepileptic drugs have thus far only been
extensively studied in rodent models, so further study is required
todeterminetheacuteneurotoxiceffectsofthesedrugsinhumans.
In the neonatal rat, administration of any of the common
antiepileptic drugs – phenytoin, phenobarbital, diazepam, clon-
azepam, vigabatrin, or valproate – all caused apoptotic neurode-
generation that was associated with reduced expression of neu-
rotrophins (Bittigau et al., 2002). Importantly, these detrimental
effectsareconsequencesofthemechanismofactionofthesedrugs
and not cross-reactivity, pharmacokinetics, or other compound-
speciﬁc toxicities. For example, apoptotic neurodegeneration is
seen in phenobarbital and diazepam, but also in other anesthet-
ics that agonize the GABAA receptor (Jevtovic-Todorovic et al.,
2003). Observations of apoptosis following anesthetics that ago-
nize GABAARs have also been reported in non-human primates,
suggesting a similar effect in humans. For example, isoﬂuorane,
whose mechanism of action includes activation of GABAARs,
inducesneuro-apoptosisinneonatalrhesusmacaques(Brambrink
et al.,2010,2012).
The two most common classes of anti-convulsant drugs are
GABAA receptor agonists and NMDA receptor antagonists. Both
NMDA receptor antagonists (Haberny et al., 2002; Hansen et al.,
2004) and GABAA receptor agonists (Bittigau et al., 2002) cause
the activation of apoptotic pathways and down-regulate neu-
rotrophins, which together cause apoptotic neurodegeneration
and inhibit neurogenesis, particularly in regions of substan-
tial neural growth in the early postnatal period such as the
sub-ventricular zone of lateral ventricles, cerebellum, and the
subgranular zone of the hippocampal dentate gyrus. Anticonvul-
sants that antagonize NMDA receptors or agonize GABAA recep-
tors cause signiﬁcant changes in the neonatal rat cerebral cortex
proteome as soon as 1day following therapy, including deregula-
tionof proteinsassociatedwithapoptosis,oxidativestress,inﬂam-
mation,proliferation,and potentiation,suggesting a multitude of
mechanisms by which such early exposure may result in neurode-
generation (Kaindl et al., 2008). Barbiturates may also alter the
developmentof synapticjunctions(DydykandRutczynski,1980).
The adverse effects of antiepileptic drugs are age-dependent.
The rodent brain undergoes a period of increased synaptoge-
nesis, glial cell multiplication, myelination, and brain network
reorganization in the ﬁrst three postnatal weeks (Dobbing,1974),
duringwhichtheneonatalratismostsusceptibletodevelopmental
toxicity from antiepileptic drugs (Kaindl et al., 2008). The corre-
sponding brain growth in humans begins during pregnancy and
lasts up to the third postnatal year (Dobbing,1974;Herschkowitz,
1988), also suggesting enhanced susceptibility to toxicity during
this period.
The changes in cell proliferation and survival signaling path-
ways induced by common antiepileptic drugs likely contribute to
altered brain morphology that is observed soon after develop-
mental exposure (Figure 2). Decreased gray matter volume and
altered gray matter morphology in a number of brain regions fol-
lowing developmental exposure to antiepileptic drugs is seen in
rodents (Ikonomidou et al., 2007). Early barbiturate administra-
tionisconsistentlyassociatedwithdecreasedbrainweight(Schain
andWatanabe,1975;Diazetal.,1977)andneuronalnumber(Yanai
et al., 1979) throughout rodent life, which is likely related to both
apoptotic neurodegeneration and inhibited neurogenesis.
LONG-TERM SIDE EFFECTS OF BENZODIAZEPINES AND
BARBITURATES
Determination of long-term cognitive and behavioral effects of
early treatment with common anticonvulsants is difﬁcult because
cognition, behavior, and neuromorphology later in life is fre-
quently heavily confounded by the condition for which anti-
convulsanttherapywasinitiallyprescribed.However,thereisgen-
eralconsensusthatneonataltherapywithagentsthatinterferewith
GABAorglutamatetransmission,includingbenzodiazepines,bar-
biturates, and phenytoin, cause cognitive and behavioral defects
later in life. These cognitive and behavioral defects have been
reported in both animal models and in humans.
Cognitive and behavioral deﬁcits are likely caused by apop-
totic neurodegeneration and inhibited neurogenesis in prolif-
erative cells in the immature brain, and by changes in neural
organization caused by the death of these neurons. Short-term
drug-induced inhibition of neurogenesis can indirectly lead to
destructionofpre-formednervepopulationsandcantherebyhave
a much broader impact on morphology later in development.
For example, neonatal administration of phenobarbital led to a
destruction of cerebellar and hippocampal granule cells, which
form early in the postnatal period, as well as cerebellar Purkinje
and hippocampal pyramidal neurons, which are formed prena-
tally, before phenobarbital was administered (Yanai et al., 1981).
Since prenatally formed nerve cell populations are culled during
synaptogenesisinnormalbraindevelopment,barbiturate-induced
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FIGURE 2 | GABA agonists affect the development of the neonatal brain.
Muscimol, a potent selective agonist for the GABAA receptor, was
administered to neonatal rats on postnatal days 0 and 1, and histologic
specimens were obtained on postnatal day 21. Representative
photomicrographs illustrate neuronal nuclear antigen-immunoreactive
neurons in the CA1 region of the hippocampus in (A) sham males, (B)
malesCmuscimol, (C) sham females, and (D) femalesCmuscimol. Musciol
treated rats have fewer neurons in the CA1 region of the hippocampus than
their sham counterparts. Scale barD100mm. Reprinted from Nunez et al.
(2003), with permission from Elsevier.
destructionof presynapticcellsthatordinarilymatureinthepost-
natal period can lead to a reduction in the number of prenatally
formed postsynaptic neurons even without direct toxicity to these
cells, since these pre-formed populations rely on synaptogene-
sis for survival through culling during development (Fishman
and Yanai, 1983). In this way, even minor neurodegeneration or
modulation of synaptogenesis during critical neurodevelopmen-
tal periods in the neonate can have major long-term effects on
network organization and cognitive and behavioral deﬁcits.
There is a wide array of reported cognitive and behavioral
changes that are associated with early anticonvulsive therapy.
Rats receiving phenobarbital show increased agitation, activity
level, and aggression (Diaz and Schain, 1978). Adult rats that
received early barbiturate therapy perform worse in cognitive
tasksaimedatassessinghippocampalfunction(Yanaietal.,1989).
Exposure to phenobarbital, phenytoin, or lamotrigine during the
second postnatal week resulted in adult deﬁcits in spatial learn-
ing, sensorimotor gating, and other behaviors in rats (Forcelli
et al., 2012). The benzodiazepine diazepam has been shown to
interfere with learning and memory in rats (Pereira et al., 1989;
Holley et al., 1995). One study found that although phenobar-
bital therapy did reduce the number of seizures in developing
rats, the cognitive deﬁcits that resulted from phenobarbital ther-
apy were greater in severity than the deﬁcits in rats that did not
receivephenobarbital,despitethefactthatthelattergroupsuffered
more seizures (Mikati et al., 1994). Phenytoin therapy altered
schedule-controlled behavior in rats that outlasted the therapy
itself (Krafft et al.,1982).
Human studies also describe similar cognitive deﬁcits. Chil-
dren aged between 6months to 3years who were placed on 1year
of phenobarbital therapy after suffering from febrile seizures
showed a negative correlation between serum levels of pheno-
barbital and memory concentration subscore of the Binet IQ
test, although no signiﬁcant difference in overall IQ or parent-
reported behavior compared to controls was reported at 8 or
12months of follow-up (Camﬁeld et al., 1979). In a much larger
study of 217 children aged between 8 and 36months with febrile
seizures, phenobarbital use signiﬁcantly lowered IQ after 2years
compared to controls, but was not associated with a signiﬁcant
reductioninseizurerecurrence(Farwelletal.,1990).Upontesting
3–5years after medication had been stopped, early phenobarbi-
tal use signiﬁcantly lowered performance in language/verbal tests
and was associated with a reduction in IQ (Sulzbacher et al.,
1999).
NOVEL TARGETS OF THE GABAergic SYSTEM: TARGETING
MOLECULES THAT ESTABLISH Cl  GRADIENTS
In the adult nervous system,due to low intracellular levels of Cl ,
GABA inhibits most neurons by activation of GABAARs, causing
Cl  inﬂux, membrane hyperpolarization, and inhibition. Addi-
tionally,GABAARactivationcanalsoinhibitneuronsvia“shunting
inhibition” by decreasing membrane resistance, which decreases
the efﬁcacy of excitatory signals to reach the critical threshold of
action potential generation (Farrant and Kaila, 2007). Under sev-
eral normal or pathophysiological circumstances,however,GABA
can depolarize and even excite neurons rather than inhibit them.
For example, in immature neurons during development and in
certain neural subpopulations in pathophysiological states,GABA
triggersdepolarizations,andpotentialexcitation(Cherubinietal.,
1991;Ben-Arietal.,1994),forreviewsee(MartyandLlano,2005).
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FIGURE 3 |WNK3 has opposite effects on NKCC1 and KCC2. Xenopus
oocytes were injected with cRNAs encoding NKCC1 (A) or KCC2 (B)
alone and in combination with wild-type or kinase-dead mutant WNK3.
86RbC inﬂux through NKCC1 (A) or efﬂux through KCC2 (B) was
determined as a measure of ﬂux through these cation Cl-channels. (A)
WNK3 activates NKCC1. NKCC1 normally shows little activity under
hypotonic conditions (180mosM) and is active in isotonic conditions
(200mM). WNK3 increases NKCC1 to maximal activity in both
conditions. Kinase-dead WNK3 strongly inhibits NKCC1 activity,
indicating phosphorylation of NKCC1 by WNK3 is necessary for activity.
*, P <0.0001 vs. NKCC1 alone. (B) WNK3 inactivates KCC2. KCC2 is
partially active under isotonic conditions and active under hypotonic
conditions. WNK3 inhibits KCC2 under both conditions. Kinase-dead
WNK3 strongly activates KCC2 under both hypotonic and isotonic
conditions. *, P <0.0001 vs. KCC2 alone.Taken together, these data
suggest that WNK3 is an important regulator of NKCC1 and KCC2
activity. Its kinase activity activates NKCC1 and inhibits KCC2. Figure
represents data from Kahle et al. (2005).
Although some have suggested that the observation of excitatory
GABA responses is experimental artifact resulting from cellular
damageinexvivo studies(BregestovskiandBernard,2012),alarge
and growing body of evidence has conﬁrmed excitatory GABA
signaling in the developing brain in vivo and its physiological
signiﬁcance during development (Ben-Ari et al.,2012).
The depolarizing effect of GABA results from a change in the
GABAA reversalpotential(EGABA)oftensecondarytoanincreased
neuronal accumulation of Cl , though HCO 
3 also plays a role.
Severalnotableionchannelsandtransportersareintegralforneu-
ronalCl  homeostasis.Amongthesearethebumetanide-sensitive
NaC-KC-Cl  co-transporter NKCC1, which transports Cl  into
thecell,andKCC2,whichnormallyextrudesit(Kahleetal.,2008b;
Blaesse et al.,2009) (Figure3).
In immature neurons, the Cl -exporting activity of KCC2 is
lower than in mature neurons (Rivera et al., 1999), and in the
context of NKCC1 expression, neuronal [Cl ]i is higher and
EGABA is more depolarized (Figure 3B). Moreover, long runs of
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action potentials in single neurons (Woodin et al., 2003), or pro-
longed seizures may result in an activity-dependent accumulation
of intracellular Cl  (Khalilov et al., 2003; Dzhala et al., 2010).
Thesedatamightprovideinsightastowhytraditionalanti-seizure
medications are less effective when given later in the course of
neonatal seizures (Painter et al.,1999).
Ion transport proteins that establish Cl  gradients across neu-
ronalmembranesandcontributetodepolarizingGABAresponses
in the immature brain could be novel targets for modulation
of the GABAergic system in treating neonatal seizures (Kahle
et al., 2008b). The commonly used loop diuretic bumetanide has
a higher afﬁnity for NKCC1 than KCC2 at low concentrations
(Isenring et al., 1998; Hannaert et al., 2002). In a human neonate
in status epilepticus (Kahle et al., 2009) and in animal models of
statusepilepticus (Dzhalaetal.,2005),bumetanidereduceselectro-
graphic seizures and exhibits synergy with phenobarbital, which
increasestheopenprobabilityoftheGABAAchannel(Dzhalaetal.,
2008).
While several studies have reported anti-convulsant effects of
bumetanide(Schwartzkroinetal.,1998;Reidetal.,2000;Mazarati
etal.,2009),othershavefoundnosigniﬁcantanti-convulsanteffect
(Ostergaard et al., 1972; Mares, 2009; Minlebaev and Khazipov,
2011).Mostofthestudiesthatdemonstrateefﬁcacyofbumetanide
were performed when it was administered with an anesthetic or
other drug that has GABA-modulatory effects,like phenobarbital.
Other NKCC1 inhibitors with greater blood-brain-barrier pene-
tration may have improved efﬁcacy. Bumetanide pro-drugs that
mask the hydrophilic acid group with esters to facilitate transport
into the brain before releasing the active molecule are currently
being tested (Loscher et al.,2013).
Currently there are two clinical trials evaluating bumetanide as
a treatment for neonatal seizures. A phase I trial (NCT00830531)
is actively enrolling patients in a randomized, double-blind,
controlled dose-escalation study of bumetanide as an add-on
therapy to treat refractory seizures caused by hypoxic-ischemic
encephalopathy. The estimated study completion date is Decem-
ber 2015. A second trial (NCT01434225) is being performed by
a large, multi-center European group in an “open-label,” dose-
escalation fashion to assess the effect of bumetanide in addition
to phenobarbital for the treatment of neonatal seizures caused
by hypoxic-ischemic encephalopathy. Data from these pilot stud-
ies will be utilized to guide the design of larger Phase III trials
that will determine the efﬁcacy of bumetanide in the treatment of
neonatal seizures.
There are some concerns about the modulation of
depolarizing GABA responses based on its importance during
neurodevelopment.Studiessuggestthe“premature”shiftofEGABA
via NKCC1-knockdown or KCC2-overexpression may result in
corticalneuronswithfewerandshorterdendrites(Canceddaetal.,
2007), less mature dendritic spines with decreased density and
increased lengths,and fewer glutamatergic inputs received by cor-
tical pyramidal neurons (Wang and Kriegstein, 2008). Some of
these observations have also been recapitulated in rats (Wang and
Kriegstein,2011).Morerigorous,long-termfollow-upinneonates
receiving bumetanide therapy is required, including comparison
with current therapies, to determine neuropsychiatric sequelae
associated with modulation of neuronal Cl  gradients in GABA
FIGURE 4 | Inhibition ofWNK3 kinase activity potently reduces
stimulatory phosphorylation of NKCC1. WNK3 regulates the
phosphorylation of NKCC1. Xenopus oocytes were injected with the
indicated cRNAs and incubated at varying extracellular osmolarities (180,
200, and 220mOsm). After incubation, oocytes were lysed, and Western
blotting was performed with probes for phosphorylated NKCC1 (P-NKCC1)
or unphosphorylated NKCC1 (NKCC1). Phosphorylation of NKCC1 normally
increases from negligible levels in hypotonic conditions (180mOsm) to
complete phosphorylation in hypertonic conditions (220mOsm).
Coexpression of NKCC1 with kinase-active WNK3 results in robust
phosphorylation of NKCC1 at all osmolarities, but coexpression with
kinase-dead WNK3 results in marked reduction of NKCC1 phosphorylation
at all osmolarities. Reprinted from Kahle et al. (2005), under their policy that
allows for the use of this ﬁgure in this review. Copyright, 2005,The National
Academy of Sciences.
transmission.Nevertheless,inthecontextof ourenhancedunder-
standing of the mechanisms of GABA signaling in the neonatal
brain, novel therapies that target Cl  homeostasis are promising
new targets for the treatment of neonatal seizures (Loscher et al.,
2013). Alternative mechanisms to modulate neuronal Cl  home-
ostasis should also be considered. One unexplored mechanism of
Cl  modulation is the manipulation of neuronal Cl  gradients
viatargetingof theserine-threonineregulatorykinasesof NKCC1
and KCC2 (Kahle et al., 2010). For example, phosphorylation of
NKCC1 at critical N-terminal threonine residues is required for
transporter activity,and this event is catalyzed by theWNK/SPAK
kinase cascade (for review, see Kahle et al., 2008a). Inhibition of
WNK3 kinase activity, a molecule expressed highly in the devel-
oping brain, is the most potent means of concurrently inhibiting
NKCC1 activity and activating KCC2 activity in vitro,and does so
via changes in transporter phosphorylation at critical regulatory
residues (Figure 4) (Kahle et al., 2005; de Los Heros et al., 2006).
Given the coordinated but reciprocal stimulatory and inhibitory
effect of phosphorylation on NKCC1 and KCC2, respectively, we
propose that inhibition of the WNK/SPAK pathway in neurons
might help restore GABA inhibition. These hypotheses are cur-
rently being explored in neuronal culture systems and whole ani-
mal models of seizures in multiple labs,including our own. These
efforts may prove useful not only for neonatal seizure manage-
ment,butalsoforadultseizuresyndromesthatexhibitdepolarized
GABA responses and altered Cl  homeostasis, such as temporal
lobe epilepsy, in which abnormal expression of Cl  channels also
rendersGABAexcitatory(Palmaetal.,2006;Huberfeldetal.,2007;
Munozetal.,2007;Brandtetal.,2010;Maaetal.,2011;Milesetal.,
2012; Eftekhari et al.,2013).
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